Understanding actionable mutations and educating patients on the safety profiles of targeted therapies are essential for the ...

Each component of an antibody-drug conjugates—payload, linker, and antibody—play a unique role in building the treatment’s use and safety profile.

Panelists discuss the growing promise of GPRC5D-targeted therapy in relapsed/refractory multiple myeloma, highlighting MonumenTAL-1 trial data showing encouraging responses in heavily pretreated ...

Panelists discuss the evolving role of bispecific antibodies in relapsed/refractory multiple myeloma, emphasizing their value as off-the-shelf options for patients post chimeric antigen receptor ...

If patients with breast cancer hyperglycemia or symptoms of it at home, a short break from capivasertib may be required, according to Hope Rugo, MD.

Most patients demonstrated at least partial response to tarlatamab in a real-world population with extensive-stage small cell ...

New therapies in breast cancer, particularly ADCs, present unique safety profiles for nurses to be aware of, according to Erika Hamilton, MD.

Data from a research database link ctDNA positivity in early breast cancer with poorer survival and higher recurrence risk.

Panelists discuss how preparing multiple myeloma patients for treatment involves structured education, emotional support, and proactive symptom management—emphasizing clear communication about the ...

Panelists discuss how treatment decisions in multiple myeloma are guided by disease risk, patient health, and evolving ...

Further data could back zanidatamab as advanced treatment for HER2-positive advanced gastroesophageal adenocarcinoma.

Panelists discuss how comprehensive patient education about expected adverse effects, combined with prophylactic measures ...